
    
      This is an open-label Phase 1 study to determine the safety and tolerability of single-agent
      treatment with AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced
      cancer that is refractory to standard therapies and a life expectancy of ≥6 months from the
      time tissue is obtained. A minimum of 6 (≤20) subjects will be enrolled to receive every
      other week subcutaneous injection of 240 μg AutoSynVax™ vaccine + 50 μg QS-21 Stimulon®
      adjuvant for up to 1 year.
    
  